Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic disorder characterized by recurrent episodic swelling of the skin, gastrointestinal tract, and airways. The core approach to treating HAE prioritizes the availability of effective on-demand acute therapy, early treatment to prevent attack progression, treatment of attacks, and long-term prophylaxis. Early treatment of all breakthrough attacks, regardless of severity and site, is critical to maximize efficacy and reduce morbidity and mortality. Ongoing management of HAE should include evaluation of breakthrough attacks and any concerns with the disease course and current therapy to decide if a therapy adjustment is warranted. In this educational series, expert faculty discuss the importance of early treatment and personalizing therapy, best practice for managing breakthrough attacks, and current and emerging therapies for HAE.
Advancing HAE Management: Mastering Personalized Care with Guideline-Driven Strategies
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, MEDCON International requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. MEDCON International mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Danny M. Cohn, MD, PhD
Department of Vascular Medicine
Amsterdam UMC
Amsterdam, The Netherlands
Dr. Cohn has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Ionis, Kalvista and Pharvaris
Consulting: Astria, CSL, Ionis, Intellia, Kalvista, Otsuka,Pharvaris, Takeda
Faculty:
Thomas Buttgereit, MD
Institut für Allergieforschung IFA
Charité – Universitätsmedizin Berlin
Berlin, Germany
Dr. Buttgereitt has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting: CSL Behring, Kalvista, All,irall, BioCryst, TakedaAnna Valerieva, MD, PhD
Department of Allergology
Medical University of Sofia
Sofia, BulgariaDr. Valerieva has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting: AstraZeneca, Berlin-Chemie/Menarini Group, CSL Behring, KalVista, Novartis, Pharming, Pharvaris, Sobi, Takeda, PharvarisLearning Objectives
After participating in this educational activity, participants should be better able to:
Evaluate best practices in personalized hereditary angioedema (HAE) treatment approaches that consider disease severity, attack frequency, and patient lifestyle and preferences as factors in individualized treatment protocols
Demonstrate understanding of best practices in the management of acute breakthrough attacks, including consideration of underlying causes and patient-specific factors
Integrate novel therapies into existing HAE treatment plans by comparing recent advances and trial data to optimize long-term outcomes and patient care
Target Audience
This activity has been designed to meet the educational needs of allergists, hematologist and dermatologists as well as all other healthcare providers involved in managing patients with hereditary angioedema.
Accreditation and Credit Designation Statements
The European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.
Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC®) for 60 minutes of effective education time.
Provider(s)/Educational Partner(s)
Today’s healthcare environment is constantly evolving and advances of medical science occur at an accelerating pace. CME/CE plays an important role in the clinical environment and is an essential element of physician training, learning, and improvement, thereby importantly contributing to optimal patient care. Since 2000, MEDCON’s mission is to deliver high quality within the world of medical education by creating forums like PACE-CME, organizing live meetings, and providing online education. We aim to stimulate the review, exchange, and assimilation of key scientific findings to improve patients’ health, to raise awareness of new science underlying various disease states, and to accelerate the translation of this information into clinical practice.
Commercial Support
This activity is supported by an independent educational grant from Kalvista Pharmaceuticals, Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MEDCON International and PACE-CME This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of PACE-CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
